N icarbazin is a broad-spectrum chemical anticoccidial agent used to prevent disease and treat infection in food-producing poultry. The drug residue is composed of equimolar quantities of 4,4-dinitrocarbanilide (DNC) and 2-hydroxy-4,6-dimethyl pyrimidine (HDP), with DNC serving as the primary component for tracking of the residue in edible tissues, including fat, muscle, liver, and kidney, and in eggs. Although nicarbazin is primarily used as a feed additive, most regulatory agencies require testing of edible tissues for residual DNC to ensure that significant levels of nicarbazin have not accumulated in the tissues of the treated animals.
Codex Alimentarius and EU Maximum Residue Limits (MRLs) and U.S. tolerances for nicarbazin, expressed as DNC concentrations, in various chicken tissues are presented in Table 1 .
On December 7-8, 2010 , an AOAC Expert Review Panel (ERP) for Veterinary Drug Residues met and reviewed 18 methods for the determination and/or confirmation of nicarbazin residues (1) . The methods reviewed were chosen based on their applicability to poultry tissues and eggs, specificity for DNC, use of broadly available technology, and avoidance of hazardous reagents. Each method was reviewed by two ERP members and the advantages and disadvantages of each method were discussed by the group. The ERP selected a multiresidue method using LC/MS/MS by Olejnik et al. (2) for further study. Recommendations to increase the suitability of the method included potential modifications to the sample size, run time, centrifugation, clean-up, detection, recovery, and applicability to fat. The use of solvent standards was recommended if no statistical difference to matrix-matched standards could be shown. The final candidate method was developed by Eurofins Central Analytical Laboratories, Metairie, LA, and is described in this paper. The candidate method provides the tissue concentration and confirmation of DNC as a marker for nicarbazin and for comparison to regulatory limits based on DNC concentration.
The AOAC Stakeholder Panel on Veterinary Drug Residues (SPVDR) met on October 2-3, 2008, and developed a general set of standard method performance requirements (SMPRs) for veterinary drug residue methods (3) . The panel considered the most stringent requirements of guidelines from major developed countries during this process. The Veterinary International Conference on Harmonization (VICH) recently published a guidance document for analytical methods to be used in residue depletion studies (4) , but the performance requirements followed for this single-laboratory validation (SLV) were in some cases more stringent than those prescribed by VICH. The parameters and criteria used for this validation are the same as those used previously for the validation of a method for determination of ractopamine in animal tissues (5) . This paper describes the SLV of the candidate method in support of First Action Official Method status through an AOAC ERP (6) .
SLV Study
The validation study was carried out by Covance Laboratories (Greenfield, IN) and included studies of linearity, matrix effect, precision, recovery/accuracy, bias, limits of detection and quantitation, and robustness. In addition to validation of method performance, data are presented for stability of the analyte in tissues, extracts, and standard solutions. Acceptance criteria are based on those developed by SPVDR (5) .
Bulk tissues were initially processed by cryogenic grinding or blending of the tissues using a food grinder to produce finely powdered homogeneous samples, then subdividing the bulk into individual test portion sizes (1.0 g for kidney, 5.0 g for all other tissues and eggs). Individual test portions were then fortified with an appropriate volume of nicarbazin standard solution. After fortification, samples were briefly vortexed on a hand vortex unit and the test portions were allowed to sit undisturbed for approximately 10-30 min before the extraction procedure was initiated to more closely approximate incurred residues. Fortified matrixes were prepared at approximately ½ MRL/tolerance, at the MRL/tolerance, and at 2x MRL/tolerance. In some cases multiple MRL/tolerance values were accommodated by adding additional fortification levels.
Incurred tissues were provided to the validating laboratory by Elanco Animal Health.
Data were subjected to the Grubbs' test for removal of outliers. 
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A. Principle
Poultry tissue is cryogenically homogenized with solid sodium sulfate, and then extracted twice with acetonitrile. Extracts are combined, filtered, and diluted accordingly based on the regulatory limits being targeted and the working concentrations of the standards used for LC/MS/MS analysis. Confirmation of identity is accomplished by comparing the product ions measured in the samples to those present in the standard injections in mass and relative intensity, and comparison of chromatographic retention times between samples and standards. Nicarbazin determination and confirmation is based on the DNC portion of the molecule as are the regulatory limits and tolerances. Concentrations are determined by LC/MS/MS using a matrix-matched standard curve and DNC-d 8 internal standard. Note: Store all stock standards and standard solutions at room temperature protected from light. Stock standards are stable for 3 months and standard solutions for 14 days under these conditions.
B. Apparatus
E. Sample Preparation
(a) Homogenization and storage of samples.-Initial processing includes grinding or blending of the tissues using cryogenic grinding to produce homogeneous samples. Cryogenic grinding is carried out by freezing the tissue with liquid nitrogen and then grinding into a fine powder using a Foss or Robot Coupe grinder or a Waring blender. This process is used to produce a very fine homogeneous powder of the tissue for analysis. Grind a minimum 500 g sample of tissue when possible. Subsamples of 5.0 ± 0.5 g of tissue (1.0 g for kidney) may be weighed into 50 mL polypropylene tubes and frozen. This will minimize tissue exposure to multiple freeze/thaw cycles. Store all tissues at freezer temperatures (-20°C or below) when not processing or subsampling. It is advisable to store fortified samples of all tissues with experimental samples to verify storage stability.
(b) Preparation of quality control (QC) and control tissues.-On the day of analysis, prepare at least seven control matrix samples and a matrix sample fortified at MRL or tolerance [QC sample, see (E)(c)(3)]. Process QC and control samples as indicated in E(c).
(c) Tissue extraction.-Poultry muscle, liver, kidney, skin with adhering fat, and eggs:
(1) Accurately weigh 5.0 ± 0.05 g (1.0 ± 0.05 g for kidney) of a representative ground sample of frozen or partially thawed sample into a 50 mL conical polypropylene centrifuge tube.
(2) Fortify all samples with 200 μL (40 μL for kidney) of the 1.0 μg/mL DNC-d 8 internal standard solution.
(3) Fortify QC samples with nicarbazin (based on DNC content and purity) at MRL or tolerance.
(4) Add 10 ± 1 g anhydrous sodium sulfate to each tissue sample. If sample size is reduced to 1 g, reduce weight of sodium sulfate by a factor of 5.
(5) Thoroughly incorporate the sodium sulfate into the tissue sample using a stainless steel or disposable wooden spatula to generate a crumbly or pasty tissue homogenate.
(6) Add 20 mL ACN and mix using a multi-tube vortex mixer for 30 min. (9) Re-extract the tissue pellet following steps (E)(c)(6)-(8) and combine the supernatants.
(10) Add 1.0 mL nicarbazin standard curve solutions to each of six control extracts to prepare the matrix-matched curve. Final concentrations are 0.5, 1.0, 2.5, 10, 25, and 50 ng/mL.
(11) Adjust all samples to 50 mL final volume with ACN and mix thoroughly.
(12) Filter the samples into LC vials for analysis.
F. Determination
(a) LC operating conditions.-Note: These guidelines may be modified to obtain the desired chromatography. Column temperature, 30°C; flow rate, 0. (d) Mass spectrometer noncompound-specific parameters.-ion source, turbospray; resolution (Q1 and Q3), unit; curtain gas (CUR), 20; ion spray (IS), -4500 V; collisional activated dissociation (CAD), 10; declustering potential (DP), -55 V; source temperature, 550°C.
(e) System suitability.-A sufficient number of injections should be made of the final control extract containing the internal standard such that the response of the internal standard has stabilized. It is left to the discretion of the analyst to determine when the y-axis response has stabilized. It may take anywhere from 5 to 10 injections for this to occur.
(f) Quantitative determination.-(1) Make single injections of the matrix-matched standard solutions, single injections of each sample extract solution, and then again single injections of the matrix-matched standard solutions. Note: Standard injections at the beginning and end of the run can be made out of the same HPLC vial. It is recommended to not exceed 12 sample injections between injections of a standard curve.
(2) Measure the peak areas for DNC and DNC-d 8 in the standard and sample solutions. Construct a 1/x weighted linear standard curve using determinative ion ratios of the standard responses (ratio of 301.0→136.7 to 308.7→140.6; DNC to DNC-d 8 ) vs concentration. From the standard curve, calculate the concentrations in ng/mL for each of the extracted samples.
(3) Using weight, volume, dilution from (F)(f)(4) if any, and concentrations from (F)(f) (2) , calculate the DNC concentration in the samples.
where A = sample concentration from standard curve (ng/mL); B = extract volume (mL); C = weight of tissue sample (g); D = dilution factor.
(4) If the determinative ion ratio exceeds the high end of the standard curve, the extracted sample should be diluted with control matrix extract and reinjected along with the standard curve.
For liver, if the tissue concentration is between 500 ng/g (equivalent of upper end of standard curve) and 8000 ng/g, the extracted sample should be diluted with control matrix extract and reinjected along with the standard curve.
For liver, if the tissue concentration of DNC exceeds 8000 ng/g, then the original tissue sample should be diluted in negative control tissue (for example, 1 g sample tissue + 4 g control tissue) and re-extracted.
(g) Qualitative confirmation.-Confirmation of identity is accomplished by comparing the product ions measured in the samples to those present in the standard injections in both mass and relative intensity.
(1) Obtain the individual ion chromatograms for the product ions and ensure that the chromatographic retention times for the analytes are ±5% relative to the mean retention time of the appropriate analyte in the standard. Extracts may be reinjected if there has been a sudden shift in retention time during the batch analysis exceeding the 5% tolerance.
(2) Integrate the area of the DNC peak for each SRM trace for the standards and samples. From the integrated area values for DNC, represent the determinative ion as 100% (m/z 301.0→136.7) and calculate the abundance of the confirmatory ion (m/z 301.0→106.9) as a relative percentage for each standard and sample. Using the mean ion abundance percentages (IAP) of the standard solutions within a chromatographic run, calculate the U.S. acceptance range (7) as mean ±20% arithmetic difference for the samples within that run. For example, at 20% relative abundance, the U.S. acceptance range would be 0-40% IAP. For the EU (8), the acceptance range depends on the IAP. For mean IAP >50%, the acceptance range is ±20% relative to mean IAP of standards. For mean ion abundance >20 to 50%, the acceptance range is ±25% relative to mean IAP of standards. For mean ion abundance >10 to 20%, the acceptance range is ±30% relative to mean IAP of standards. For mean ion abundance ≤10%, the acceptance range is ±50% relative to mean IAP of standards. For example, at 20% mean IAP, the EU acceptance range would be 14-26% for the samples within that run.
(h) Standard curve acceptability criteria.-The following criteria will be used for determining curve acceptability: (1) Back-calculated accuracy for any standard curve point must be within ±15% of the theoretical value (±20% of the theoretical value at the lower limit of quantitation).
(2) Individual data points may be excluded in a given batch provided the curve maintains a minimum of five different concentrations and the standards bracket the QC and unknown test portions.
(i) QC acceptability criteria.-The following criteria will be used for determining QC acceptability:
(1) Determine recovery of the QC test portions as recovery = (concentration/actual fortification level) × 100.
(2) QC test portions must meet the recovery requirements (e.g., 60-110% at <100 ng/g for U.S. Food and Drug Administration).
Results and Discussion
Matrix Effect
Standard solutions were compared to matrix-matched standards for muscle, liver, kidney, and skin/fat by constructing a standard curve in matrix extract or in solution and determining the standard curve slopes for each set of experiments. Skin/fat had the largest matrix effect, causing a decrease of 13.2% in the standard curve slope. Muscle had the smallest matrix effect with a decrease of 4.4%, and liver and kidney yielded matrix effects of 10.1 and 6.2%, respectively. Because these matrix effects are <20%, the method was made more efficient by utilizing solution standards, which allows for the analysis of multiple tissue types in a single chromatographic run.
Matrix Study-Fortified Tissues
Because the matrix effects were small, the method was initially developed with solution standards and did not include an internal standard. For determination of recovery and precision, matrixes were fortified at the concentrations indicated in Table 2 , bracketing the Codex MRL and U.S. tolerance concentrations.
Repeatability precision was determined by testing six replicates at each fortification concentration in three independent trials. The independent trials included at least two operators and were performed on at least 2 different days. Intra-and intertrial means, standard deviations (s r ), and relative standard deviations (RSD r ) were calculated at each concentration for each matrix. Precision data are presented in Table 2 . Acceptance criteria are based on the RSD r values. At concentrations <100 ng/g DNC, the RSD r must be ≤20% and at concentrations ≥100 ng/g DNC, the RSD r must be ≤10%.
Eggs were the only matrix fortified with nicarbazin at <100 ng/g DNC. The intra-trial RSD r values for eggs at 50 ng/g DNC ranged from 2.1 to 12.1%, and the intertrial RSD r value was 8.6% and, thus, was within the acceptance criterion. At concentrations ≥100 ng/g DNC, the intra-trial RSD r values ranged from 0.70 to 11.6% and intertrial RSD r values ranged from 2.5 to 11.3% across all tissue types. There were six instances of intra-trial RSD r values above 10%, including one each in liver, kidney, and eggs, and three in fat, ranging from 10.2 to 11.6%. Only one tissue, muscle, yielded an intertrial RSD r value above the acceptance criterion, 11.3%, and only at one concentration (200 ng/g). Intra-trial RSD r values for muscle were all below 10%, ranging from 0.81 to 7.0%.
HorRat values are a measure of the observed precision compared to the theoretical precision at a given concentration (9) and are calculated for repeatability as HorRat r = RSD r , %/ PRSD r , %, where PRSD r , % = C Table 3 . Average recoveries ranged from 82% in eggs to 98% in kidney tissue, and thus the method met the acceptance criteria for recovery in all tissue types tested.
The bias values for each fortification concentration are listed in Table 2 . Bias is defined as the difference between the mean candidate result and the fortification concentration (bias = [mean cand ] -[fortification]). The average percent bias (bias/[fortification] × 100) across concentrations was determined for each matrix from the slope of the regression line after plotting the mean bias against the fortification concentrations. The average percent bias from these plots is related to the average percent recovery as recovery -bias = 100%. The average percent bias values are listed in Table 3 . Kidney tissue had the smallest absolute average bias at -2.3% and eggs had the largest absolute average bias at -17.8%. There is no acceptance criterion for bias.
Twenty replicate test portions of control tissue were analyzed to determine the LOD for nicarbazin in each tissue type. The estimated LOD is defined as the mean result plus three standard deviations. Estimated LOD values for each matrix/tissue are presented in Table 3 . Note that these data were generated using the original method developed without internal standard and with solution standards. An estimated LOD could not be determined for liver and muscle, as all results from the control tissue analyses were 0.00 ng/g. For those tissues where at least one replicate yielded a non-zero result, the estimated LOD values ranged from 0.37 to 2.90 ng/g. LOQ was determined by fortifying control matrixes at 1/10 Codex MRL. Because there is no MRL for eggs, the LOQ was validated at the same level as the other tissues. Ten test portions of each fortified matrix were extracted and analyzed according to the candidate method. Note that these data were generated using the original method developed without internal standard and with solution standards. Two data points were determined as outliers per the Grubbs' test and removed from the analysis for muscle tissue. RSD r values were ≤20% in all matrixes tested, which met the precision criterion (RSD r ≤20% at concentrations <100 ng/g), validating the LOQ at 20 ng/g (Table 4 ).
Matrix Study-Incurred Tissues
The repeatability precision of the method was verified with incurred tissues from liver, kidney, muscle, and fat as listed in Table 5 . Each animal was dosed through ingestion of feed containing the drug. Three replicate analyses were carried out for each available tissue using the original method developed without internal standard and with solution standards. The repeatability precision (RSD r ) varied from 0.53 to 2.5%. The precision with incurred residue tissues is very tight and well within the limits established for the acceptance criteria.
Matrix Study-Modified Method
Initial method development data demonstrated no significant matrix effect and little difference in method performance with or without internal standard (ISTD). While the average recoveries for all matrixes were within the acceptable limits for the initial method, the individual recovery values for chicken liver at the lower concentrations were below 80% (76.7% at 100 ng/g; 75.5% at 200 ng/g; and 78.5% at 400 ng/g). To improve the accuracy of the method, a study was carried out in chicken liver using a modified method including matrix-matched standards and DNC-d 8 ISTD. Chicken liver was fortified at six concentrations and six replicates at each concentration were processed and analyzed on 2 different days. The data are presented in Table 6 for the modified method with and without ISTD. When ISTD is included, the data are referred to as accuracy. In the absence of ISTD, the data are referred to as recovery. When ISTD is included, all data points, as well as the means, meet the acceptance criteria for both precision and accuracy/recovery. Without ISTD, the recoveries are still acceptable, but the values at the lower concentrations are improved when ISTD is used. The authors recommend applying the modified method to all matrixes to ensure maximum accuracy. This revised method is reported herein and representative chromatograms are shown in Figure 1 .
To evaluate the linearity of the improved method, DNC standard curve solutions in chicken liver extract with internal standard were analyzed in triplicate and a weighted (1/x) regression was performed. Residual analysis revealed small random residuals indicating linearity was achieved. The residuals ranged from -0.07 to 6.0%, with the highest residual percentages occurring at the two lowest concentrations. All residuals were within the acceptable range.
Confirmatory Ion Abundance Percentages
There are two criteria for confirmation of analyte in LC/MS/MS methods: (1) the retention time of the analyte in an unknown sample must be within 5% of the mean retention times observed in the standards; and (2) the IAP of the confirmatory product ion in an unknown sample must be within a specified range of the mean IAP observed in the standards (depending on whether U.S. or EU criteria are followed). Both criteria must be met in order for an unknown sample to be considered confirmed.
One transition ion (m/z 300.95→106.88) was examined for confirmation of DNC. The IAP is determined from the relative abundance of the confirmatory ion compared to the determinative ion (m/z 300.95→136.88). IAP values from each of the standards within a chromatographic run were averaged and the IAP of each sample within that run was compared to the mean IAP value of the standards. There were two sets of standards analyzed in each run, one set at the beginning and one set at the end of each run. Both U.S. (7) and EU (8) confirmatory IAP criteria were used for comparison. The U.S. criterion for confirmation using two transition ions is an IAP value within 10% (arithmetic) of the mean IAP of the standards in that run. The EU criteria vary by the abundance as follows: at IAP >50%, tolerance is ±20% relative to the mean IAP of standards; at IAP >20 to 50%, tolerance is ±25% relative to the mean IAP of standards; at IAP >10 to 20%, tolerance is ±30% relative to the mean IAP of standards; and at IAP ≤10%, tolerance is ±50% relative to the mean IAP of standards. For example, a mean standard IAP of 50% would have acceptance ranges of 40-60% (±10% arithmetic) in the United States and 37.5-62.5% (±25%) in the EU for samples within that run.
A sample having an analyte retention time or an IAP value outside the acceptance range is considered a false-negative result. False negatives are known positive samples that do not meet the confirmation criteria. Data were collected from the fortified and incurred samples in the matrix studies from the method performed with solution standards and without ISTD.
All analyte retention times for the unknown samples were within 5% of the retention times of the standards for that run. The mean IAP of standards varied from 7.2 to 9.5% across all runs examined. There were no false-negative results observed out of 484 fortified samples and 12 incurred samples examined by the U.S. and EU criteria for an overall estimated false-negative rate of 0.00% (95% confidence limits 0.00%, 0.74%).
Robustness
Chicken muscle was used as the matrix for the robustness study. Nine test portions of control tissue were fortified with 1000 ng DNC and the method was performed as initially developed, with solution standards and without ISTD. The method parameters used to test the robustness of the method included tissue weight, sodium sulfate weight, vortex time, shaking time, tissue temperature, fortification residence time, and injection volume.
Parameter conditions were tested according to the Plackett-Burman design (10) in which seven parameters are varied and tested in eight treatment combinations as shown in Table 7 . The resulting recoveries for DNC were determined for each treatment combination. Not surprisingly, the recoveries appear to correlate with injection volume. After correction for injection volume, all treatment combinations were within the recovery criterion (80-110% at ≥100 ng/g), indicating that varying the remaining parameters had no significant effect on the method performance.
The data were also analyzed by multiple linear regression to determine whether any parameter variation is critical. Successive rounds of regression analysis were performed, each time eliminating the most nonsignificant variable to allow more degrees of freedom for estimation of error, until only one variable was left. As observed above, this variable was injection volume, with a P-value from the analysis of variance of 0.000115 (data not shown). When the recoveries were adjusted for injection volume, no significant parameters were found.
Stability Studies
Stability of DNC was examined in tissues, extracts, and standard curve solutions. Stability is defined as less than a 20% change in mean concentration or calibration slope. First, fortified tissue was frozen at -20°C, and then tested at 0, 14, and 28 days of storage. Mean DNC concentrations were compared to those of freshly fortified tissue, and stability was demonstrated in all tissues out to the 28 day time point (data not shown). The largest change was 9.8% in kidney tissue after 28 days, but all other tissues were less than 5%. Next, fortified tissue extracts were stored at 2-8°C, and then analyzed at 0, 1, and 3 days. Mean concentrations were compared to those of freshly fortified tissue. All tissue extracts showed acceptable stability out to 3 days (data not shown).
Additionally, fortified tissues were subjected to freeze-thaw cycles. Tissues were prepared and examined after 0, 1, 2, or 3 repeated freeze-thaw cycles. Test portions were placed into a freezer set at -20°C for a minimum of 18 h to freeze, and then placed on the bench top at room temperature to thaw unassisted. The cycle was repeated as needed. Mean concentrations at each cycle were compared to those of freshly fortified tissue. DNC was shown to be stable for 3 freeze-thaw cycles in all tissue types (data not shown).
Finally, the standard curve solutions were subjected to stability testing at 2-8°C. The stored standard curve solutions were compared to freshly prepared standard curve solutions and tested at 0, 1, 3, 7, and 14 days. After analysis, the peak area ratios were plotted against concentration, and the concentration of each standard solution was calculated from the regression equation of the freshly prepared solutions. The standard solutions were deemed stable at each time point if (1) the back-calculated concentrations of the stored standard solutions were within 20% of those of the freshly prepared standard solutions, and (2) the slope resulting from regression analysis of the stored standard solutions did not differ from the slope of the fresh standard solutions by more than 20%. With the exception of the 2.5 ng/mL standard solution, the standard curve solutions met the acceptance criteria for stability in general (data not shown). There were two instances (1.0 ng/mL at day 3 and 0.5 ng/mL at day 14) where the standard curve solutions were outside the acceptable range for stability. The 2.5 ng/mL standard solution was significantly outside of the acceptability limit at 3 days and beyond. The % differences seen for the 2.5 ng/mL solution are somewhat out of line with the other data points and could warrant further investigation. The standard curve slopes were all within the acceptance criteria.
Conclusions
Data from fortified and incurred tissues generated by the initial candidate method with solution standards and without ISTD met the acceptance criteria for the determination of nicarbazin (DNC) in chicken tissues as established by the AOAC Stakeholder Panel for Veterinary Drug Residues for SLV studies. The method, however, had lower than desired recoveries at low DNC concentrations in chicken liver (76-79% at 100-400 ng/g) and, therefore, was revised to include matrix-matched standards and an ISTD to ensure accuracy in all tissue types at all concentrations. This revised method yielded accuracy values between 93 and 99% and repeatability 1.2e4
1.3e4
1.4e4
1.5e4 values (RSD r ) between 1.8 and 6.2% at fortification levels from 100-8000 ng/g in chicken liver and is presented here. It is expected that the revised method will perform at least as well in other chicken tissue types, including kidney, muscle, skin/ fat, and eggs. Data for the revised method in these additional tissues will be available in the near future. Data from the initial candidate method demonstrated the ability of the method to confirm analyte, with no false negatives observed in 484 fortified samples and 12 incurred samples analyzed according to U.S. and EU confirmatory criteria. Robustness studies of the initial candidate method demonstrated no critical method parameters except for injection volume. Because injection volume is easily controlled with an autoinjector, the method is considered robust. Finally, DNC was shown to be stable in frozen tissue for up to 28 days and up to 3 freeze-thaw cycles; in chilled tissue extract for up to 3 days; and in chilled standard solutions for up to 14 days. The revised method presented here meets the stakeholder panel criteria in chicken liver at all concentrations tested and was granted First Action Official Method status on May 7, 2013.
